Chiusura precedente | 0,7207 |
Aperto | 0,7098 |
Denaro | 0,7440 x 100 |
Domanda | 0,8010 x 100 |
Min-Max giorno | 0,6900 - 0,7815 |
Intervallo di 52 settimane | 0,5800 - 59,0400 |
Volume | |
Media Volume | 362.569 |
Capitalizzazione | 6,353M |
Beta (mensile su 5 anni) | 1,38 |
Rapporto PE (ttm) | 0,01 |
EPS (ttm) | 109,2800 |
Prossima data utili | 12 ago 2024 - 16 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 720,00 |
First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced its FDA authorized VLN® reduced nicotine content cigarettes designed specifically to promote tobacco h
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting com
BUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company’s tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements,